| INTRODUCTION
Hepatitis C virus (HCV) is increasingly transmitted among HIV-positive men who have sex with men (MSM), engage in high-risk sexual practices and do not identify themselves as intravenous drug users. [1] [2] [3] [4] [5] [6] We and others have shown that reductions in high-risk practices associated with HCV transmission combined with widespread use of direct-acting antivirals (DAA)-based HCV treatment could reduce HCV incidence and prevalence. 7, 8 In some countries including Switzerland 
| MATERIALS AND METHODS

| The Swiss-HCVree-trial
The Swiss 
| Mathematical model of an intensive intervention
To simulate the effect of intensive interventions, we extended a previously developed model of HCV transmission among HIV-positive MSM in Switzerland. 7 The model uses a system of ordinary differential equations where the population is classified into 24 compartments defined by (i) stage of HCV infection (uninfected, infected, and on treatment); (ii) HCV genotype (1or 4 and 2 or 3); (iii) risk behaviour (with and without high-risk practices associated with HCV transmission); (iv) enrolment in HIV-care; and (v) enrolment in the intensive intervention. The model assumes that a fraction of patients reporting condomless anal sex with occasional partners also engage in practices associated with HCV transmission. Model parameters are described in Table 1 and Table S1 . Of note, we estimated that the SHCS included 84% of all HIV-positive MSM in Switzerland. 13, 14 Patients enrolled in the pangenotypic intervention infected with all genotypes were treated within 3 months since the beginning of the intervention. Analogously, in the SwissHCVree-trial patients infected with genotypes 1 or 4 were treated within 9 months from the beginning of the trial.
We modelled the following scenarios for patients not enrolled in intensive interventions and for everyone after the completion of the intervention.
| Scenarios outside intensive interventions
| Treatment in clinical routine
We assumed HCV treatment outside intensive interventions or in the absence of intensive interventions (Figure 1 ) to be DAA-based resulting in 95% sustained virological response (SVR). 
| High-risk behaviour in the overall (HIVpositive men who have sex with men) population
We considered two main scenarios where the fraction of individuals engaging in high-risk practices associated with HCV transmission: (i) remained stable at the value estimated for 2016 (14%, labelled stable high-risk behaviour) or (ii) declined continuously to reach a 50% reduction by 2025 (labelled reduced high-risk behaviour).
| Projections on the effect of intensive interventions
The overall projection period was 2016-2025. Based on the scenarios depicted above, we reported trajectories, short-term (end-of-intervention, ie, May 2017) and long-term (2025) HCV prevalence, incidence, genotype distribution and cumulative number of treatment episodes.
We undertook independent analyses that assumed (i) no intensive intervention; (ii) the pangenotypic intervention; and (iii) the SwissHCVree-trial. We only projected genotype distribution with the
Swiss-HCVree-trial (as treatment is subtype independent in (i) and (ii)). All these projections correspond to HIV-positive MSM living in
Switzerland, including those who are not enrolled in HIV-care.
| Projections with the Swiss-HCVree-trial restricted to Swiss HIV cohort study participants
To allow comparison of these results with SHCS data in the future, we also reported separate model projections with the Swiss-HCVree-trial restricted to the subset of modelled individuals enrolled in the SHCS.
| Sensitivity analyses
We undertook three sensitivity analyses for MSM enrolled in the SHCS.
These analyses assumed: (i) further increase in high-risk behaviour in 
| RESULTS
At the beginning of the screening period, 4257 MSM were enrolled in the SHCS. Simulated HCV prevalence and incidence at the beginning of the trial were 5.8% and 2.6 per 100 person-years, respectively. Further characteristics of the modelled population are described in detail in. Little differences between the two scenarios of high-risk behaviour in the overall population were observed in these short-term simulations.
| Long-term projections (2025)
If we assumed stable high-risk behaviour in the overall population, expected prevalence in 2025 without intensive interventions ranged from 13.1% to 0.7% across scenarios of treatment rate in clinical routine 
| Cumulative number of treatment episodes (2016-2025)
In the F2 scenario, the pangenotypic intervention increased the cumulative number of treatment episodes by 35% (from 214 to 288) when assuming stable high-risk behaviour in the overall population ( Figure 3B ). But with much shorter time from HCV infection to treatment in clinical routine, the pangenotypic intervention was predicted to reduce treatment episodes with respect to no intensive intervention.
For instance, if time from HCV infection to treatment in clinical routine was 2 years and high-risk behaviour in the overall population stable, the pangenotypic intervention reduced the cumulative number of treatment episodes by 36% (from 678 to 431).
| Projections on the effect of the Swiss-HCVreetrial
Model projections with the pangenotypic intervention and those with the Swiss-HCVree-trial were close (Figs. S1 and S2). However, as expected, the Swiss-HCVree-trial was less effective at reducing HCV prevalence and treatment episodes than the pangenotypic intervention.
These results are reported in detail in the Supplementary Material.
In all scenarios, reduced high-risk behaviour in the overall population was more successful than either the pangenotypic intervention or the Swiss-HCVree-trial at reducing HCV prevalence in the long term ( Figure 3 and Fig. S2A ). Reduced high-risk behaviour in the overall population led to similar outcomes ( Figure 4B and Fig. S3B ). But as expected, the postintervention speeds of increase in prevalence and incidence were much lower in this case.
| Expected trajectories of HCV prevalence, HCV incidence and genotype distribution with the Swiss-HCVree-trial
In the F2 scenario, simulated incidence with the Swiss-HCVreetrial surpassed that without intensive intervention in mid-2019 and remained slightly above until the end of the projection period (Fig. S3) .
Because only patients infected with genotypes 1 or 4 are enrolled in the Swiss-HCVree-trial, a comparative advantage for the spread of genotypes 2 and 3 is imminent. Figures 4C and 4D show the projected genotype distribution when assuming stable and reduced high-risk behaviour in the overall population.
In the F2 scenario, the proportion of infections with genotypes 2 or 3 increased from 11% in 2016 to up to 27% in 2025. Earlier HCV treatment in clinical routine led to smaller changes in genotype distribution ( Figures 4C and 4D ). This occurs because treatment in clinical routine is homogeneous across genotypes. Early treatment therefore shrinks the discrepancy between genotypes imposed by the Swiss-HCVree-trial. 
| Projections with the
| Sensitivity analyses
The outcomes of the sensitivity analyses are reported in the supple- 
| Strengths and limitations
To our knowledge, this is the first published study to use a mathematical model to project the population level impact of a clinical trial or other intensive interventions to tackle HCV transmission. The strengths and limitations of the core model have been discussed elsewhere.
7
We believe the main strength of the mathematical model developed in the present study is that it emulates the dynamics of sexually The lack of data on the role of HCV infections acquired through high-risk practices abroad could limit the accuracy of our predictions. 
| Outlook
We aim to assess the accuracy of our model projections by comparing them with the real end-of-study effects of the Swiss-HCVree-trial. The core transmission model is largely based on data from the SHCS and was shown to reproduce the epidemic accurately. 7 However, comparing model outcomes with real data will help evaluate and improve the extent to which the model structure and underlying assumptions capture the key aspects of the dynamics of sexually transmitted HCV and its response to specific interventions. 
| Implications of findings
